Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 5/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.34 |
| ▸ | IL1B | P01584 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2808557 | 0.74 | SLC22A12 (0.40) | SLC22A12HTR6 | |
| SCHEMBL2807534 | 0.70 | PRKAB2 (0.38) | PTGER4 | |
| SCHEMBL2811077 | 0.69 | SLC22A12 (0.38) | SLC22A12PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5913507 | 0.64 | MAOA (0.42) | HDAC6 | |
| SCHEMBL2808531 | 0.64 | REN (0.37) | SLC22A12 | |
| SCHEMBL4315681 | 0.64 | PNMT (0.33) | — | |
| SCHEMBL16040906 | 0.63 | ADRB2 (0.44) | HDAC6 | |
| SCHEMBL662617 | 0.61 | XDH (0.35) | PTGER4CNR2 | |
| SCHEMBL13132400 | 0.60 | SLC22A12 (0.39) | SLC22A12HDAC6CNR2 | |
| SCHEMBL664894 | 0.60 | P2RX7 (0.36) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | SLC22A12 2804/4885HTR6 1848/4885PDE4A 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.